Scisparc Ltd. SPRC
Annual
Quarterly
FY2024 · ended Dec 31, 2024 · Revenue $1.31M, -54.6% YoY · Filed Apr 24, 2025
Scisparc Ltd. (SPRC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $1.3 million and a net loss of $7.5 million. As of Dec 31, 2024 it held $1.5 million in cash and investments and $48,000 in total debt.
Revenue
$1.31M
-54.6% vs prior year
Net income
$-7.47M
-27.0% vs prior year
Operating cash flow
$-5.10M
+13.3% vs prior year
Free cash flow
$-7.92M
-55.5% vs prior year
EPS
$1.28
-91.1% vs prior year
Dividend per share
None
Shares outstanding
365,444
-96.6% vs prior year
Net cash
$1.49M
FY 2024
Operating margin
-560.2%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1611746
- Former names
- SciSparc Ltd./ADR (until Aug 27, 2021); Therapix Biosciences Ltd. (until Jan 28, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $2.9M | $1.3M | — | — |
| Operating income | -$7.3M | -$6.8M | -$8.3M | -$5.8M | -$3.3M |
| Net income | -$7.5M | -$5.9M | -$2.6M | -$5.8M | -$3.5M |
| Diluted EPS | $1.28 | $14.43 | — | — | $0.11 |
| Operating cash flow | -$5.1M | -$5.9M | -$7.9M | -$5.1M | -$4.3M |
| Free cash flow | — | — | -$7.9M | -$5.1M | — |
| Total assets | $10.3M | $11.2M | $10.6M | $9.9M | $2.6M |
| Stockholders' equity | $8.9M | $9.6M | $6.4M | $8.1M | $1.4M |
| Cash and investments | $1.5M | $2.1M | $3.6M | $6.9M | $1.9M |
| Total debt | $48,000 | $76,000 | $27,000 | $18,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 26, 2026 |
| 6-K | Current report (foreign issuer) | Oct 23, 2026 | Oct 23, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Oct 7, 2026 | Oct 7, 2026 |
All 607 Scisparc Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.